InvestorsHub Logo
Post# of 252302
Next 10
Followers 19
Posts 727
Boards Moderated 0
Alias Born 11/10/2009

Re: bladerunner1717 post# 153110

Wednesday, 11/28/2012 11:19:23 AM

Wednesday, November 28, 2012 11:19:23 AM

Post# of 252302

Is the HCC indication enough to make you a buyer?

The short answer is yes. ARQL's tivantinib has shown to be active in multiple indications. The 2nd-line, HCC Phase 2 results are compelling. Given that it was a randomized, double-blind trial, i'm hoping the results can be replicated in the phase 3, however, it is going to be a long wait with few new catalysts (mCRC) to drive the stock in the near-term.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.